Manufacturing mesenchymal stromal cells for phase I clinical trials

被引：43

作者：

Hanley, Patrick J. ^{[1
,2
]}

Mei, Zhuyong ^{[1
,2
]}

Cabreira-Hansen, Maria da Graca ^{[3
]}

Klis, Mariola ^{[1
,2
]}

Li, Wei ^{[1
,2
]}

Zhao, Yali ^{[1
,2
]}

Durett, April G. ^{[1
,2
]}

Zheng, Xingwu ^{[4
]}

Wang, Yongping ^{[4
,5
]}

Gee, Adrian P. ^{[1
,2
]}

Horwitz, Edwin M. ^{[4
,5
]}

机构：

[1] Texas Childrens Hosp, Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA

[2] Methodist Hosp, Houston, TX 77030 USA

[3] St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX USA

[4] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA

[5] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA

来源：

CYTOTHERAPY | 2013年 / 15卷 / 04期

基金：

美国国家卫生研究院;

关键词：

clinical trials; Good Manufacturing Practices; mesenchymal stromal cells; phase I trials; BONE-MARROW; STEM-CELLS; BLOOD; CHILDREN; CULTURE; THERAPY; LIVER;

D O I：

10.1016/j.jcyt.2012.09.007

中图分类号：

Q813 [细胞工程];

学科分类号：

100113 [医学细胞生物学];

摘要：

Mesenchymal stromal cells (MSCs) are multipotent progenitor cells capable of differentiating into adipocytes, osteoblasts and chondroblasts as well as secreting a vast array of soluble mediators. This potentially makes MSCs important mediators of a variety of therapeutic applications. They are actively under evaluation for immunomodulatory purposes such as graft-versus-host disease and Crohn's disease as well as regenerative applications such as stroke and congestive heart failure. We report our method of generating clinical-grade MSCs together with suggestions gathered from manufacturing experience in our Good Manufacturing Practices facility.

引用

页码：416 / 422

页数：7

共 27 条

[1]

Immunosuppressive Properties of Mesenchymal Stem Cells [J].